Organization
Merck KGaA
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Merck KGaA
... Last month, the FDA warned that immuno-oncology stars from Merck and Roche might actually be hurting some previously untreated bladder cancer patients' ...
... of the transfer membrane market in the forecast period. As of 2017, Merck KGaA (US) dominates the global transfer membrane market through its broad product ...
... Another day, another approval for Merck immuno-oncology star Keytruda. On Wednesday, the drugpicked up an FDA green light ...
... Merck's Keytruda has a new indication, and with it, immunotherapy has moved into ...
... genome editing and novel processes to ensure products meet the highest standards Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in ...
... patients with MET-positive advanced cancers Given evolving standard of care in HCC, Merck KGaA, Darmstadt, Germany will assess the potential of tepotinib in combination for ...
... shape the possibilities of tomorrow. Follow MilliporeSigma onTwitter@MilliporeSigma, onFacebook@MilliporeSigma and onLinkedIn. All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same ...
... be explored in tumors and settings where addressing both mechanisms could leadtoimprovedclinicaloutcomes Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its ...
... Merkel cell carcinoma (mMCC), a rare and aggressive type of skin cancer Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in ...
... are consistent with data previously reported, with no new safety signals identified Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its ...
Subscribe now for full coverage on Merck KGaA
Start My Free Trial